5913 Results

People

  1. Ladanyi
    Ladanyi
  2. Solit
    Solit
  3. Levine
    Levine
  4. Berger
    Berger
  5. Schultz
    Schultz
  6. Arcila
    Arcila
  7. Hakimi
    Hakimi
  8. Chandarlapaty
    Chandarlapaty
  9. Zehir
    Zehir
  10. Mellinghoff
    Mellinghoff

Groups

  1. Human Oncology and Pathogenesis Program (5913)
  2. GSK Faculty (5696)
  3. Department of Medicine (4258)
  4. Department of Pathology and Laboratory Medicine (3036)
  5. Tow Center for Developmental Oncology (TCDO) (2612)
  6. Solid Tumor Oncology Division (2599)
  7. Sloan Kettering Institute Postdocs (1984)
  8. Hematologic Malignancies, Division of (1879)
  9. Center for Hematologic Malignancies (1845)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (1735)
  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (2984)
  2. Meeting Abstract (2526)
  3. Review (137)
  4. Editorial (106)
  5. Book Section (54)
  6. Research Letter (41)
  7. Guidelines (18)
  8. Correspondence (16)
  9. Miscellaneous (15)
  10. Conference Paper (13)
  11. Book Whole (3)
Groups
  1. Human Oncology and Pathogenesis Program (5913)
  2. GSK Faculty (5696)
  3. Department of Medicine (4258)
  4. Department of Pathology and Laboratory Medicine (3036)
  5. Tow Center for Developmental Oncology (TCDO) (2612)
  6. Solid Tumor Oncology Division (2599)

More Groups

People
  1. Marc Ladanyi (1326)
  2. David Solit (779)
  3. Ross Levine (774)
  4. Michael Berger (765)
  5. Nikolaus Schultz (486)
  6. Maria Arcila (426)

More People

Years
  1. 2025 (119)
  2. 2024 (359)
  3. 2023 (402)
  4. 2022 (451)
  5. 2021 (380)
  6. 2020 (457)

More Years

Publications
  1. Journal of Clinical Oncology (636)
  2. Blood (495)
  3. Cancer Research (412)
  4. Modern Pathology (299)
  5. Clinical Cancer Research (268)
  6. Laboratory Investigation (262)

More Publications

Publishers
  1. American Association for Cancer Research (871)
  2. Nature Publishing Group (757)
  3. American Society of Clinical Oncology (702)
  4. American Society of Hematology (541)
  5. Elsevier Inc. (420)
  6. Nature Research (312)

More Publishers

Results (5913)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Generation and characterization of novel preclinical disease models of NSCLC with NRG1 rearrangements to improve therapy
    Meeting Abstract

    Gladstone, E.; Vojnic, M.; Offin, M.; Delasos, L.; Lui, A.; Siau, E.; Sato, H.; Benayed, R.; Kurth, R.; Mattar, M.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Validation and implementation of ultra-rapid mutation and MSI assessment using the Idylla platform
    Meeting Abstract

    Nafa, K.; Momeni Boroujeni, A.; Gandia, E.; Solomon, J. P.; Vakiani, E.; Zhu, M.; Chan, R.; Elezovic, D.; Mensah, N. T.; Rijo, I.; more...
    Journal of Molecular Diagnostics (2019)

    Fulltext@MSK | Save
  • Integrated germline and somatic analysis identifies actionable cancer predisposing germline mutations in 9,734 patients with advanced cancers
    Meeting Abstract

    Jayakumaran, G.; Mandelker, D.; Birsoy, O.; Jairam, S.; Li, Y.; Yang, C.; Somar, J.; Rai, V.; Syed, A.; Benayed, R.; more...
    Journal of Molecular Diagnostics (2019)

    Fulltext@MSK | Save
  • The impact of metastatic sites on checkpoint inhibitor outcomes in patients with cutaneous and unknown primary melanoma
    Meeting Abstract

    Krieger, P.; Sanchez-Vega, F.; Schultz, N.; Shoushtari, A.
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers
    Meeting Abstract

    Ma, J.; Klatt, M.; Dundar, F.; Zumbo, P.; Femia, M.; Betel, D.; Scheinberg, D.; Baker, B.; Klebanoff, C.; Chandran, S.
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • In vivo study (MYCEC0617) of CD34+-HSC and CEC mutational profile for investigating cell origin and pathogenesis of primary myelofibrosis (PMF)
    Meeting Abstract

    Farina, M.; Bernardi, S.; D'Adda, M.; Foroni, C.; Zanaglio, C.; Dunbar, A.; Re, F.; Cattina, F.; Rambaldi, B.; Zollner, T.; more...
    Haematologica (2019)

    Fulltext@MSK | Save
  • Prognostic value of FDG-PET/CT in recurrent/refractory CNS lymphoma receiving Ibrutinib-based therapies
    Meeting Abstract

    Krebs, S.; Wolfe, J.; Mellinghoff, I.; Grommes, C.; Schoder, H.
    European Journal of Nuclear Medicine and Molecular Imaging (2019)

    Fulltext@MSK | Save
  • INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753)
    Meeting Abstract

    von Mehren, M.; Serrano, C.; Bauer, S.; Gelderblom, H.; George, S.; Heinrich, M.; Schöffski, P.; Zalcberg, J.; Chi, P.; Jones, R. L.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S.; Chou, J. F.; Gabler, A. R.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Won, E.; Sanchez-Vega, F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
    Journal Article

    Hastings, K.; Yu, H. A.; Wei, W.; Sanchez-Vega, F.; DeVeaux, M.; Choi, J.; Rizvi, H.; Lisberg, A.; Truini, A.; Lydon, C. A.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save